AMS vs TOI โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
TOI Captures Institutional Edge (3โ1 Pillars ยท 5โ5 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to The Oncology Institute, Inc. Common Stock (TOI) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while AMS counters with relative strength in Valuation. Fundamentally, AMS trades at 44.6x Forward P/E with -7.4% operating margin (+19.2% YoY revenue) versus TOI at N/M Forward P/E and -4.4% operating margin (+41.2% YoY). In options structure, AMS sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against TOI sits in SURGE (35th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | AMS Revenue | TOI Revenue | AMS Op. Margin | TOI Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $20M | N/A | 9.4% | N/A | AMS |
| FY2019 | $20M | N/A | 7.5% | N/A | AMS |
| FY2020 | $20M | $190M | -53.1% | -4.4% | TOI |
| FY2021 | $20M | $200M | 7.7% | -22.6% | AMS |
| FY2022 | $20M | $250M | 12.3% | -32.5% | AMS |
| FY2023 | $20M | $320M | 1.3% | -23.8% | AMS |
| FY2024 | $30M | $390M | -9.9% | -15.3% | AMS |
| FY2025 | $30M | $500M | -12.8% | -7.2% | TOI |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | AMS | TOI | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $7.2M | $506.9M | Larger Scale | TOI |
| Trailing P/E Ratio Valuation | 44.6x | N/M | Lower Multiple | AMS |
| Forward P/E Ratio Valuation | 44.6x | N/M | Lower Multiple | AMS |
| Revenue Growth (YoY) Growth | +19.2% | +41.2% | Higher Growth | TOI |
| Operating Margin (TTM) Profitability | -7.4% | -4.4% | Higher Margin | TOI |
| Net Profit Margin Profitability | -5.8% | -8.0% | Higher Margin | AMS |
| Return on Equity (ROE) Capital Efficiency | -12.1% | -651.7% | Higher ROE | AMS |
| 52-Week Range Position Momentum | 6% ($1โ$2) | 65% ($2โ$7) | Stronger Trend | TOI |
| Beta / 30D Volatility Risk Regime | 0.18ฮฒ ยท 46% Vol | 1.66ฮฒ ยท 73% Vol | Lower Realized Risk | AMS |
| Unified Institutional Score Composite Signal | 33.8 / 100 (SELL) | 53.5 / 100 (HOLD) | Higher Composite | TOI |